RxDoctor Payments Data

Joseph Adiyody, MD

Internal Medicine · Babylon, NYNPI 1568491868

Payments from drug & device makers

$18,207in general payments, 2019–2025

Across 689 payments — averaging $26.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mannkind Corporation$6K
  • GSK$1K
  • Boehringer Ingelheim$1K
  • Pfizer$953
  • AstraZeneca$909
  • Novo Nordisk$818
  • plus $7K from 37 others

What the payments were for

  • Consulting fees$2251%
  • Food & beverage$17,97599%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,207 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$378,513
Medicare patients
239
Services billed
10,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide90$130,211
EliquisApixaban88$62,603
JardianceEmpagliflozin47$39,180
OzempicSemaglutide30$29,537
FarxigaDapagliflozin Propanediol33$25,312
Tresiba Flextouch U-100Insulin Degludec12$9,285
BrilintaTicagrelor14$5,935
VascepaIcosapent Ethyl16$5,612
Rosuvastatin Calcium399$4,180
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$3,755
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$2,478
Albuterol Sulfate HfaAlbuterol Sulfate64$2,367
Valsartan144$2,212
Metoprolol Succinate133$2,100
Memantine Hcl24$1,633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$812$130,21190 claims
PfizerEliquis$953$62,60388 claims
Boehringer IngelheimJardiance$1,082$39,18047 claims
AstraZenecaFarxiga, Brilinta$909$31,24747 claims
Novo NordiskOzempic$818$29,53730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Babylon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →